ArticleWorld journal of gastrointestinal oncology2025
Clinical value of contrast-enhanced ultrasound in early diagnosis of hepatocellular carcinoma.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContrast-enhanced ultrasound (CEUS) offers valuable reference data for the early diagnosis of hepatocellular carcinoma (HCC) through dynamic enhancement patterns and quantitative analysis.
aimTo evaluate the clinical value, diagnostic accuracy, and imaging characteristics of CEUS in the early diagnosis of HCC and its correlation with HCC pathological findings.
methodsThis single-center retrospective study included 125 patients suspected of having primary liver cancer who underwent CEUS at the Department of Hepatobiliary Surgery and Imaging of our hospital from January 2022 to March 2024. All patients were diagnosed with HCC
resultsOf the 125 patients, 66.40% were male, with a mean age of 56.74 ± 11.25 years. Conventional type HCC accounted for 71.20%, with histological grades I (14.40%), II (51.20%), and III-IV (34.40%). CEUS enhancement patterns included "fast-in and fast-out" (36%), "fast-in and slow-out" (40%), and "continuous enhancement" (24%). APT < 15 seconds was observed in 40% of patients, and PEI ≥ 1.5 in 56%. Correlation analysis revealed significant negative correlations between tumor differentiation grade and APT, washout completion time, and longest diameter (
conclusionCEUS holds significant clinical value in the early diagnosis of HCC, as it effectively identifies the typical imaging characteristics of early-stage HCC through dynamic contrast enhancement and quantitative analysis, particularly during the arterial and portal phases. As a non-invasive, cost-effective, and efficient imaging modality, CEUS has a broad clinical application potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.